AtaiBeckley (ATAI) EBITDA Margin (2021 - 2026)
AtaiBeckley (ATAI) recorded quarterly EBITDA Margin of 3239.1% in Q1 2026, down 147.27% quarter-over-quarter from 1309.97% in Q1 2025, and down 192913.0% on a YoY basis from N/an in Q1 2025.
AtaiBeckley (ATAI) EBITDA Margin (2021 - 2026) Analysis & Trends
AtaiBeckley has disclosed EBITDA Margin across 5 years of filings, most recently posting 3796.53% for Q3 2025.
- EBITDA Margin for Q3 2025 came in at 3796.53%, up 5270847.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 3438.02% (up 2857920.0% YoY), and the FY2024 annual result was 33341.23%, up 661768.0% from the prior year.
- EBITDA Margin was 3239.1% for Q1 2026 at AtaiBeckley, down from 1309.97% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1309.97% in Q1 2025 to a low of 3239.1% in Q1 2026.
- The 5-year median for EBITDA Margin is 20219.77% (2021), against an average of 60266.07%.
- Across the five-year window, EBITDA Margin sank 14755410 bps in 2022 and soared 12925216 bps in 2023, its largest moves.
- AtaiBeckley's EBITDA Margin stood at 19641.3% in 2021, then tumbled by 403 bps to 98855.26% in 2022, then sank by 89 bps to 186450.0% in 2023, then tumbled by 35 bps to 252208.33% in 2024, then soared by 98 bps to 3796.53% in 2025.
- The last three EBITDA Margin figures came in at 3796.53% (Q3 2025), 3515.02% (Q2 2025), and 1309.97% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | -3,239.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,239.10% |
| Sep 30, 2025 | -3,796.53% |
| Jun 30, 2025 | -3,515.02% |
| Mar 31, 2025 | -1,309.97% |
| Mar 31, 2025 | -1,309.97% |
| Dec 31, 2024 | -252,208.33% |
| Sep 30, 2024 | -56,505.00% |
| Jun 30, 2024 | -9,424.54% |
| Dec 31, 2023 | -186,450.00% |
| Sep 30, 2023 | -30,843.68% |
| Jun 30, 2023 | -18,524.42% |
| Mar 31, 2023 | -89,767.57% |
| Dec 31, 2022 | -98,855.26% |
| Sep 30, 2022 | -160,095.83% |
| Jun 30, 2022 | -20,798.24% |
| Dec 31, 2021 | -19,641.30% |
| Sep 30, 2021 | -12,541.73% |
| Mar 31, 2021 | 20.37% |